| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
|
Toi, Masakazu
|
|
|
22 |
1 |
p. 74-84
|
artikel
|
| 2 |
APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma
|
Reni, Michele
|
|
|
22 |
1 |
p. 10-11
|
artikel
|
| 3 |
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox
|
Dubsky, Peter
|
|
|
22 |
1 |
p. e18-e28
|
artikel
|
| 4 |
Cancer burden, finance, and health-care systems
|
Wells, James M
|
|
|
22 |
1 |
p. 13-14
|
artikel
|
| 5 |
Cancer care prioritised: Georgia expands access to cancer medicines
|
Khizanishvili, Gvantsa
|
|
|
22 |
1 |
p. 15-17
|
artikel
|
| 6 |
Carcinogenicity of acrolein, crotonaldehyde, and arecoline
|
|
|
|
22 |
1 |
p. 19-20
|
artikel
|
| 7 |
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
|
O'Hara, Mark H
|
|
|
22 |
1 |
p. 118-131
|
artikel
|
| 8 |
Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study
|
Fernandez, Laura M
|
|
|
22 |
1 |
p. 43-50
|
artikel
|
| 9 |
Considering benefit and risk before routinely recommending SpaceOAR
|
Hall, William A
|
|
|
22 |
1 |
p. 11-13
|
artikel
|
| 10 |
Correction to Lancet Oncol 2020; 21: 1574–88
|
|
|
|
22 |
1 |
p. e5
|
artikel
|
| 11 |
Correction to Lancet Oncol 2020; 21: 1602–10
|
|
|
|
22 |
1 |
p. e5
|
artikel
|
| 12 |
Correction to Lancet Oncol 2021; 22: 8–9
|
|
|
|
22 |
1 |
p. e5
|
artikel
|
| 13 |
Correction to Lancet Oncol 2020; 21: 1549–50
|
|
|
|
22 |
1 |
p. e5
|
artikel
|
| 14 |
Correction to Lancet Oncol 2020; 21: 1023–34
|
|
|
|
22 |
1 |
p. e5
|
artikel
|
| 15 |
COVID-19 and systemic anticancer therapy: exploiting uncertainty
|
Gelderblom, Hans
|
|
|
22 |
1 |
p. 3-5
|
artikel
|
| 16 |
Cuts in cancer research funding due to COVID-19
|
Burki, Talha Khan
|
|
|
22 |
1 |
p. e6
|
artikel
|
| 17 |
Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study
|
Yamashita, Rikiya
|
|
|
22 |
1 |
p. 132-141
|
artikel
|
| 18 |
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
|
Goldman, Jonathan W
|
|
|
22 |
1 |
p. 51-65
|
artikel
|
| 19 |
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
|
Laubach, Jacob P
|
|
|
22 |
1 |
p. 142-154
|
artikel
|
| 20 |
ESTRO 2020 Online Congress
|
Landman, Allison
|
|
|
22 |
1 |
p. 22-23
|
artikel
|
| 21 |
Facebook groups for alternative treatments for cancer: advertising masquerading as community support
|
Sissung, Tristan M
|
|
|
22 |
1 |
p. 25-26
|
artikel
|
| 22 |
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
|
Tan, Antoinette R
|
|
|
22 |
1 |
p. 85-97
|
artikel
|
| 23 |
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|
Boorjian, Stephen A
|
|
|
22 |
1 |
p. 107-117
|
artikel
|
| 24 |
Mixed acinar and macrocystic ductal prostatic adenocarcinoma
|
Giganti, Francesco
|
|
|
22 |
1 |
p. e37
|
artikel
|
| 25 |
Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum
|
Dent, Rebecca
|
|
|
22 |
1 |
p. 27-28
|
artikel
|
| 26 |
Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?
|
Kulkarni, Girish S
|
|
|
22 |
1 |
p. 8-9
|
artikel
|
| 27 |
62nd ASH Annual Meeting and Exposition
|
Gourd, Katherine
|
|
|
22 |
1 |
p. 24
|
artikel
|
| 28 |
Pandemics and the health of a nation
|
The Lancet Oncology,
|
|
|
22 |
1 |
p. 1
|
artikel
|
| 29 |
Preoperative radiotherapy for retroperitoneal sarcoma
|
Izzuddeen, Yousra
|
|
|
22 |
1 |
p. e3
|
artikel
|
| 30 |
Preoperative radiotherapy for retroperitoneal sarcoma
|
Chowdhary, Mudit
|
|
|
22 |
1 |
p. e2
|
artikel
|
| 31 |
Preoperative radiotherapy for retroperitoneal sarcoma
|
DeLaney, Thomas
|
|
|
22 |
1 |
p. e1
|
artikel
|
| 32 |
Preoperative radiotherapy for retroperitoneal sarcoma – Authors' reply
|
Bonvalot, Sylvie
|
|
|
22 |
1 |
p. e4
|
artikel
|
| 33 |
Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative
|
Extermann, Martine
|
|
|
22 |
1 |
p. e29-e36
|
artikel
|
| 34 |
RAPIDO protocol: a promising approach for high-risk locally advanced rectal cancers
|
Saklani, Avanish
|
|
|
22 |
1 |
p. 2-3
|
artikel
|
| 35 |
Reporting cancer care outcomes from the private sector
|
Burki, Talha Khan
|
|
|
22 |
1 |
p. 21-22
|
artikel
|
| 36 |
Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?
|
Bartsch, Rupert
|
|
|
22 |
1 |
p. 5-6
|
artikel
|
| 37 |
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
|
Bahadoer, Renu R
|
|
|
22 |
1 |
p. 29-42
|
artikel
|
| 38 |
Should stereotactic ablative body radiotherapy be the standard of care in oligometastatic cancer?
|
Correa, Rohann J M
|
|
|
22 |
1 |
p. 6-8
|
artikel
|
| 39 |
2020 SNO virtual meeting
|
Costa, Márcia
|
|
|
22 |
1 |
p. 18
|
artikel
|
| 40 |
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
|
Chalkidou, Anastasia
|
|
|
22 |
1 |
p. 98-106
|
artikel
|
| 41 |
The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis
|
Clark, James J
|
|
|
22 |
1 |
p. 66-73
|
artikel
|
| 42 |
The genomic landscape of breast cancer brain metastases: a systematic review
|
Morgan, Alexander J
|
|
|
22 |
1 |
p. e7-e17
|
artikel
|
| 43 |
WHO launches strategy to accelerate elimination of cervical cancer
|
Das, Manjulika
|
|
|
22 |
1 |
p. 20-21
|
artikel
|
Tijdschrift beschrijving